Back to Results
First PageMeta Content
Clinical research / Lipid storage disorders / Lysosomal storage diseases / Pharmaceutical industry / Glycogen storage disease type II / Enzyme replacement therapy / Fabry disease / Alglucosidase alfa / Clinical trial / Health / Medicine / Rare diseases


Pompe Community Update News from Patient Advocacy Summer 2011 Pompe Phase 2 Co-administration Study: AT2220-010 Amicus Therapeutics’ Pompe Program is proceeding with a Phase 2 co-administration study of AT2220, the inv
Add to Reading List

Document Date: 2011-08-10 11:05:44


Open Document

File Size: 197,62 KB

Share Result on Facebook

City

Washington / DC / Seattle / Loma Linda / Los Angeles / San Antonio / Montreal / Birmingham / /

Country

Switzerland / United Kingdom / Peru / /

/

Facility

American College of Medical Genetics / /

IndustryTerm

healthcare professionals / healthcare / keyword search / /

MedicalCondition

Gaucher diseases / Fabry disease / larger lysosomal storage disease / allergic reactions / Pompe disease / /

MedicalTreatment

enzyme replacement therapy / /

Organization

Latin American Society of Inborn Errors of Metabolism and Neonatal Screening / United Pompe Foundation / American Society for Human Genetics / Society for the Study of Inborn Errors / Muscular Dystrophy Association / Pompe Patient Advisory Board / Amicus’ Pompe Patient Advisory Board / the American College / FDA / Society for Inherited Metabolic Diseases / Amicus / International Pompe Association / /

Person

Jayne C. Gershkowitz / /

/

Position

principal investigator / Director / Patient Advocacy & Public Policy Phone / /

Product

Myozyme / /

ProgrammingLanguage

Cedar / /

ProvinceOrState

New Jersey / California / /

Technology

pharmacokinetics / antibodies / /

URL

www.amicustherapeutics.com / www.pompestudy.com / www.clinicaltrials.gov / /

SocialTag